Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine as an Adjuvant to Levobupivacaine in Subarachnoid Anesthesia in Total Hip Arthroplasty
NCT06577155Phase 2Completed
- Sponsor
- Asklepieion Voulas General Hospital
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nalbuphine in pain (2 arms), sponsored by Asklepieion Voulas General Hospital. Primary endpoints: Morphine consumption at 24 hours and Numeric Rating Scale at 48 hours. Started Aug 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06577155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577155.